Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.

To combat long-overlooked fungal pathogens, researchers and regulators must embrace innovative science and policy.

Only four new antifungal drugs were approved over the last decade. The WHO urges for safer treatments and improved diagnostics, especially in low and middle-income countries, to address this ...